SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 4 — Focused Visit (Follow-up) — Charles Darwin — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientCharles Darwin
Date of birth1809-02-12
IdentifiersMRN HR-NI003-SYN-TD; SSN (made up) 000-03-2967
Document date1849-06-09
AuthorBernard Ashworth, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Three-month review of cyclic vomiting syndrome on amitriptyline. [S]

History of Present Illness

Mr. Darwin returns eight weeks after starting amitriptyline. The dose was raised to 50 mg after two weeks and to 75 mg four weeks ago, by portal message. He had one episode two weeks into treatment; he took the sumatriptan spray and an ondansetron tablet within half an hour of the prodrome, and it settled in about ten hours without emergency care. He has had no episode in the four weeks since reaching 75 mg, and his cold three weeks ago passed without one. He has a dry mouth, mild constipation, and some grogginess in the first hour of the morning, and has gained 1 kg. He has no dizziness on standing, palpitations outside the prodrome, or urinary hesitancy. He practices the relaxation breathing most evenings and has not yet started cognitive behavioral therapy. No ECG was done at the 50 mg step, because the increase was made by portal message. [S]

ElementDetail
MedicineAmitriptyline 75 mg at bedtime for four weeks
EpisodesOne in eight weeks, aborted at the prodrome; none at 75 mg
Side effectsDry mouth, mild constipation, morning grogginess; weight up 1 kg
Self-managementRelaxation breathing most evenings; trigger plan followed

Review of Systems

SystemResultFinding
GastrointestinalPositiveMild constipation; no vomiting in four weeks
Ears, nose, mouth, and throatPositiveDry mouth
CardiovascularNegativeNo palpitations, chest pain, or fainting
NeurologicalPositiveGrogginess in the first hour of the morning; no dizziness on standing
PsychiatricNegativeMood steady; less worried about going out; no thoughts of self-harm

5 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Amitriptyline 25 mg oral tablet, one tablet at bedtimeOne tablet by mouth at bedtimeOral route1849-04-14 to 1849-04-28completedS
Amitriptyline 50 mg oral tablet, one tablet at bedtimeOne tablet by mouth at bedtimeOral route1849-04-28 to 1849-05-12completedS
Amitriptyline 75 mg oral tablet, one tablet at bedtimeOne tablet by mouth at bedtimeOral route1849-05-12activeS
Sumatriptan 20 mg nasal spray, one spray at the first sign of an episodeOne spray in one nostril at the start of the prodrome; may repeat once after 2 hours; no more than 2 sprays a day or 6 a weekNasal route1849-04-14activeS
Ondansetron 8 mg orally disintegrating tablet at the first sign of an episodeDissolve one tablet on the tongue at the start of the prodrome, then every 8 hours as needed during an episodeOral route1849-04-14activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
1849-06-09Body height183cmS
1849-06-09Body weight72.4kgS
1849-06-09Body mass index (BMI) [Ratio]21.6kg/m2S
1849-06-09Systolic blood pressure118mm[Hg]S
1849-06-09Diastolic blood pressure74mm[Hg]S
1849-06-09Heart rate72/minS
1849-06-09Respiratory rate14/minS
1849-06-09Body temperature36.6CelS
1849-06-09Oxygen saturation in Arterial blood by Pulse oximetry99%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
1849-06-09Q-T interval corrected436ms<=450 msNormalS
1849-06-09Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ]6{score}S
1849-06-09Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]4{score}S

Physical Exam

Vital signs recorded on 1849-06-09; see the Vital Signs section. [S]

SystemFinding
GeneralWell; weight 72.4 kg
CardiovascularRegular rhythm at 72 per minute; blood pressure 118/74 mmHg, with no drop on standing
AbdomenSoft and non-tender

Problems

ProblemClinical statusVerificationCodeProvenance
Cyclic vomiting syndrome, moderate to severe, meeting Rome IV criteria after a normal work-up; provisional clinical diagnosisactiveprovisional R11.15S — Synthetic provisional diagnosis at the gastroenterology consultation, anchored to his documented episodic vomiting. It is clinical, with no confirmatory test, and does not confirm any historical theory.
Recurrent episodes of nausea and vomiting over more than a year, with prodromal trembling, palpitations, and dizziness, and flatulence and fatigue between episodes; cause under evaluationresolvedconfirmed R11.2S — Synthetic presenting concern at the index visit, superseded by the provisional diagnosis at the six-week visit; the episodic vomiting is documented (D).
Common cold, without a vomiting episode; resolvedresolvedconfirmed J00S — Synthetic intercurrent illness at an unscheduled visit; chosen because infection is a common trigger of cyclic vomiting and because cold medicines interact with amitriptyline. It does not echo a documented illness.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
Self-managementEpisode diary: number, length, and severity of episodes, prodrome, emergency visits, and missed workEvery visitCompleted todayOne episode in eight weeks, about ten hours, aborted at the prodrome; none in four weeks at 75 mg
ExaminationRome IV criteria and red flags (vomiting between episodes, weight loss, nocturnal pain, neurological signs, onset after 50)At diagnosis and with any change in patternCompleted todayPattern unchanged; no red flags
LaboratoryBlood count, electrolytes and glucose, liver panel, lipase, urinalysis, TSH, cortisol, celiac serologyAt diagnosis between episodes; repeat only for an atypical episodeUp to dateNormal at diagnosis; no atypical episode to prompt a repeat
ImagingUpper endoscopy and small-bowel imaging (CT enterography)Once at diagnosisUp to dateNormal at diagnosis; no repeat needed
ImagingGastric emptying studyNot routine; only between episodes when gastroparesis is suspectedNot indicatedNo symptoms of gastroparesis
Medication safetyECG with QTc on amitriptyline and ondansetron (below 450 ms in men)Baseline, at about 50 mg during titration, and at the target doseDeferredThe ECG due at about 50 mg was not done, a deviation from the guideline: the dose was raised by portal message without an ECG order. Judging by today's tracing at 75 mg (QTc 436 ms, sinus rhythm), no harm resulted. Corrective action: dose changes are now made at a visit or with an ECG ordered at the same time
Medication safetyECG with QTc on amitriptyline and ondansetron (below 450 ms in men)Baseline, at about 50 mg during titration, and at the target doseCompleted todayQTc 436 ms at the target dose of 75 mg, up from 412 ms at baseline and below 450 ms; sinus rhythm at 72
Medication safetyAmitriptyline tolerability: drowsiness, dry mouth, constipation, dizziness on standing, weightEach visit on treatmentCompleted todayDry mouth, mild constipation, morning grogginess; weight 72.4 kg (up 1.0 kg); no dizziness on standing
SurveyMood and thoughts of self-harm on a tricyclic (PHQ-9)Each visit on treatmentCompleted todayPHQ-9 4, with item 9 scored 0
SurveyAnxiety screen (GAD-7)At diagnosis, then every three monthsCompleted todayGAD-7 6, down from 8
Medication safetyAbortive plan: timing and response to sumatriptan nasal spray and ondansetron, and dose limitsEvery visitCompleted todayUsed once, within half an hour of the prodrome, with the episode settling in about ten hours; within dose limits
Self-managementIndividualized emergency department protocol letterAt diagnosis; update with any change in treatmentUp to dateLetter carried; not needed
Self-managementTriggers: sleep, meals, travel, social stress, infectionsEvery visitCompleted todayRegular meals and sleep kept; a cold three weeks ago passed without an episode
Self-managementCannabis and other substance use, and hot-bathing behavior (cannabinoid hyperemesis syndrome)At diagnosis and yearlyUp to dateNo cannabis use
ExaminationComorbidities: migraine, orthostatic and autonomic symptoms, sleep disordersAt diagnosis and yearlyUp to dateNo migraine or orthostatic symptoms; sleep regular
Medication safetyMitochondrial supplements (coenzyme Q10, riboflavin)Conditional; consider with a partial responseNot indicatedEarly response to amitriptyline; reconsider only if the response becomes partial
Medication safetyAlternative prophylaxis (topiramate or aprepitant)Only if amitriptyline fails or is not toleratedNot indicatedAmitriptyline effective and tolerated
Self-managementRelaxation training, meditation, or biofeedback; cognitive behavioral therapy offeredOngoingCompleted todayBreathing practice most evenings; cognitive behavioral therapy still offered
ExaminationWeight and hydrationEvery visitCompleted today72.4 kg; well hydrated

Goal progress:

Guideline basis: Guidelines on management of cyclic vomiting syndrome in adults by the American Neurogastroenterology and Motility Society and the Cyclic Vomiting Syndrome Association (2019); Anxiety Disorders in Adults: Screening (2023)

Follow-up: Preventive health visit in about six weeks. Six-month review in three months, after three months at the target dose. Next scheduled visit 1849-07-21: preventive health visit. [S]